These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34105395)

  • 1. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
    Sun L; Wang C; Wu C; Zhou Y; Wang C
    Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
    Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
    Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
    Kridin K
    Dermatol Ther; 2020 Jul; 33(4):e13790. PubMed ID: 32506731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
    Nieto-Benito LM; Bergón-Sendín M; Pulido-Pérez A; Rosell-Díaz ÁM; Parra-Blanco V; Suárez-Fernández R
    Exp Dermatol; 2021 Sep; 30(9):1345-1351. PubMed ID: 34028898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis.
    Hung CT; Chang YL; Wang WM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Bellinato F; Maurelli M; Schena D; Gisondi P; Girolomoni G
    Ital J Dermatol Venerol; 2021 Aug; 156(4):455-459. PubMed ID: 32545941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus.
    Chanprapaph K; Pratumchart N; Limtong P; Rutnin S; Sukasem C; Kungvalpivat P; Triamchaisri S; Suchonwanit P
    J Dermatol; 2021 Apr; 48(4):486-496. PubMed ID: 33543537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
    Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
    J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
    Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
    J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
    Nakatani K; Noborio R; Nomura Y; Ueki Y; Kiyohara T; Hashimoto T
    J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.